Category: GLP-1s

One in 8, or 12% of adults said they have taken GLP-1s and 6% of adults said they currently take the drugs, KFF Health reported May 10.

A blockbuster drug class that includes Ozempic, Wegovy and Trulicity is pioneering avenues in the healthcare industry and redefining obesity care as the weight loss therapy market stretches toward $100 billion. 

In February, Novo Nordisk agreed to buy Catalent for $16.5 billion. The Federal Trade Commission has since requested more information from the companies as it reviews the deal, The Wall Street Journal reported May 3. 

Delayed gastric emptying, also known as gastroparesis, is a more common side effect of GLP-1s than other diabetes and weight loss treatments, according to new research.

Demand for Type 2 diabetes drug Ozempic is high across the U.S., but interest varies by state, according to research conducted by Bison Pharmacy. 

Hospital pharmaceutical costs marginally decreased in 2023 because of the lessened need for COVID-19 drugs, but overall healthcare spending on drugs grew 13.5% — largely because of weight loss medications, a new study found. 

Nearly 4 million Medicare patients could be eligible to have Wegovy covered after the FDA approved it to reduce risk of heart attack and strokes, KFF reported April 24.

Debates are swirling about surgery disruptions, a baby boom phenomenon and additional uses for Ozempic and other glucagon-like peptide-1 medicines. 

Since summer 2023, physicians have recommended patients taking GLP-1s, such as Ozempic or Mounjaro, to skip a dose before an elective surgery. Researchers from Stanford Medicine say this might be unnecessary and create adverse effects. 

Four more solutions of Zepbound and Mounjaro are in limited supply, and the shortages have prolonged, the FDA said April 17.